Ferguson et al. first described that the combination of siRNA-mediated EPHB4 knockdown with topoisomerase I inhibition diminished SCLC cell viability in vitro, while, when co-applied with paclitaxel, inducing tumor regression in vivo [72]. The gene discussed is EPHB4; the disease is neoplasm.